NATIONAL INSTITUTES OF HEALTH

Researchers at Johns Hopkins Kimmel Cancer Center found MYC gene activation initiates and progresses prostate cancer, initially attracting immune cells but later hiding the tumor. This discovery could lead to new therapeutic targets.

Researchers from the University of Michigan Health Rogel Cancer Center developed a model to predict treatment response in bladder cancer patients using short-term three-dimensional organoid models, aiming to guide personalized treatment decisions.

USC's AI for AD project, led by Paul Thompson and Jose-Luis Ambite, uses federated learning to analyze MRI scans and blood tests for early Alzheimer’s detection, aiming to personalize treatments and discover new drugs.

CHIP and mCAs increase breast cancer risk and colorectal cancer mortality. CHIP linked to higher breast cancer risk (HR, 1.30; 95% CI, 1.03-1.64; P =.02) and colorectal cancer death (HR, 2.50; 95% CI, 1.32-4.72; P = .004). mCAs with cell fraction >5% raise breast cancer risk (HR, 1.39; 95% CI, 1.06-1.83; P =.01) and colon cancer death (HR, 2.19; 95% CI, 1.11-4.3; P =.02).

NIH report provides 17 recommendations to improve NEC scientific evidence, emphasizing prevention of preterm birth as key to reducing NEC. The report highlights gaps in understanding NEC's development, particularly in relation to feeding practices and human milk's role. Additional research is needed to optimize nutrition and feeding methods for preterm infants, enhance milk production, and reduce disparities in lactation and donor milk access.

New research finds that following the MIND diet for 10 years significantly reduces the risk of cognitive decline, with women experiencing a 6% lower risk. The diet combines elements of the Mediterranean and DASH diets, emphasizing brain-healthy foods while limiting unhealthy ones.

Clarivate Plc unveils Citation Laureates 2024, forecasting Nobel Prize recipients based on extraordinary citation records and societal impact. This year's 22 laureates span six countries and have made significant contributions to fields like clean energy, nanotechnology, and quantum computing.

Oregon State University researchers received a $1.2 million NIH grant to develop an AI-powered device using saliva analysis for personalized epilepsy treatment, aiming to optimize anti-seizure medication dosing and reduce side effects.

A NIH-supported trial found pomalidomide, a bone marrow cancer drug, effective in treating hereditary hemorrhagic telangiectasia (HHT), reducing nosebleeds and improving quality of life. Published in the New England Journal of Medicine, the trial was stopped early due to significant positive results, offering hope for HHT patients who previously had no reliable treatment.

Pomalidomide, approved for multiple myeloma, significantly reduces severe nosebleeds in HHT patients, improving quality of life, according to the PATH-HHT study published in the New England Journal of Medicine.